LifeTechnologies为研究人员从科研到临床应用的转移做好准备
预先配置的工具和试剂，以支持细胞**的临床转化
Life Technologies公司（纳斯达克代码：LIFE）今天宣布了GIBCO®细胞**体系（CTS™）的诞生，它将提供生命科学行业中*广阵容的产品线，以支持包括再生医学在内的细胞**应用。该产品组合是专门为协助细胞**研究人员加速从科研到临床应用的转变而设计，将包括深层而广泛的Invitrogen设备和试剂。
如今，细胞**研究人员往往需要花费大量的时间和**，将推动一个细胞**概念从实验室环境转移到临床所需的工具和试剂进行组合和验证，使之成为一个符合监管且可获得高度支持的过程。基于细胞的**有着数以千计的潜在应用，有望应对尚有待解决的医疗需求，包括神经障碍、心脏病、自体****、传染病，以及传统**不起作用的组织修复。随着再生医学领域经历爆炸式的增长，在未来的15年将从16亿美元增长到150-200亿美元1，LifeTechnologies正在打造一个打包的工具和试剂组合以应对这个挑战，并协助研究人员加速将有潜力的方案转移到临床环境的过程。
“文档是将**的细胞**带到临床的关键之一，”加利福尼亚州Duarte希望城生物医学和遗传学中心的主管，应用技术开发中心的**副总裁和创始人LarryCouture博士认为。“在临床前开发阶段以及临床试验过程中的更深入阶段，有适当的质量体系，合适的文档以及稳定的供应链很关键。”
CTS产品组合将提供培养基、试剂、酶、缓冲液、生长因子、分选磁珠和磁铁，以及完整流程方案中的其他组成部分。高质量的材料将提供容易获取的文献资料，如分析证明书和原产地证明书。此外，将为产品提供*高程度的技术支持、监管支持以及网络支持。
“我们凭借我们的专业知识以及广泛而深入的产品组合来创建细胞**的流程方案，它将协助研究人员更快更高效地从科研应用进入到临床，同时增强患者的**性，”LifeTechnologies细胞**系统的总经理PaulPickering谈到。“我们期望所提供的这些产品能让我们与这个领域的核心***建立合作，并在他们准备将细胞**概念转移到临床时协助他们减轻验证工具和试剂的负担，这*终将改善人类状况，并解决尚未满足的医疗需求。”
科学顾问新市场回顾，引用自Fierce Biotech 2010年4月23日的文章。
关于Life Technologies (http://www.lifetechnologies.com) LifeTechnologies公司（纳斯达克代码：LIFE）是一家致力于改善人类环境的全球生物技术公司。我们的仪器、耗材和服务可协助研究者加速科学探索与开发，从而让生命变得更加美好。我们的客户遍及生物学各个领域，努力加速推进个性化**、再生科学、分子诊断、农业和环境的研究以及21世纪的法医鉴定。生命科技公司2009年的销售额为33亿美元，全球雇员约为9000人，遍及160个国家，并拥有将近3900项知识产权**及专有许可证。LifeTechnologies公司由Invitrogen公司和AppliedBiosystems公司合并而成，制造体外诊断产品和仅供研究的产品。更多关于我们如何起作用的信息，请访问网站www.lifetechnologies.com。
Life Technologies的**声明
本新闻稿包含关于我们预期结果的前瞻性陈述，且涉及多种风险和不确定因素。本新闻稿中的部分内容，包括但不限于，行业趋势、LifeTechnologies的业务计划、目标、预期和战略的陈述，均包含受各种风险和不确定因素影响的前瞻性陈述，这些风险和不确定因素可能导致实际结果和事件与前瞻性陈述中明示或暗示的有重大差异。任何不属于历史事实的陈述均为前瞻性陈述。可以通过一些特定用词，如“相信”、“计划”、“意图”、“预期”、“目标”、“估计”、“期望”，和/或将来时态、条件句结构（如“将”、“可能”、“可以”、“应当”等）或类似的表达方式，来识别一部分前瞻性陈述。可能引发实际结果与前瞻性陈述有重大差异的一些重要因素，在LifeTechnologies向美国证券交易委员会提交的文件中皆有详述。LifeTechnologies不承担任何更新或修改此类前瞻性陈述，以反映后续事件或情形的义务。
LifeTechnologies Readies Researchers for Transition from Benchtop toBedside
Tools and reagents pre-configured to supportcell therapy clinical translation
CARLSBAD, Calif. – June 16, 2010 – Life Technologies Corporation(NASDAQ: LIFE) today announced the formation of GIBCO® Cell Therapy Systems (CTS™), which will offer the life scienceindustry’s widest array of products to support cell therapyapplications, including regenerative medicine. Specificallydesigned to help cell therapy practitioners accelerate thetransition from research to clinical applications, the productportfolio will include a broad and deep offering of Invitrogendevices and reagents.
Cell therapy practitioners today spend a lot of time and moneyassembling and qualifying the tools and reagents required to move acell therapy concept from a laboratory environment to the clinic ina regulatory compliant and highly supported process. Cell-basedtherapies have hundreds of potential applications addressing unmetmedical needs, including neurological disorders, heart disease,cancer, auto-immune disease, infectious disease, as well as tissuerepair where conventional pharmaceuticals may be ineffective. Withthe regenerative medicine field experiencing explosive growth, from$1.6 billion to $15 - $20 billion over the next 15 years1, LifeTechnologies is building a portfolio of bundled tools and reagentsto address this challenge and help researchers accelerate theprocess of moving their potential solutions into a clinicalenvironment.
“Documentation is a critical aspect of bringing novel celltherapies to the clinic,” said Dr. Larry Couture, Senior VicePresident and Founding Director of the Center for AppliedTechnology Development; Director for the Center for Biomedicine andGenetics at the City of Hope in Duarte, California. “Having properquality systems in place, appropriate documentation, and a stablesupply chain is critical, both in the pre-clinical developmentphase, as well as further down the road during clinicaltrials.”
The CTS product portfolio will provide media, reagents, enzymes,buffers, growth factors, selection-beads and magnets, and othercomponents of integrated workflow solutions. The high-qualitymaterials will come with easily accessible documentation, such ascertificates of analysis and certificates of origin. Moreover, theproducts will be backed up with the highest level of technical,regulatory and web-based support.
“We’ve leveraged our expertise, as well as our broad and deepproduct portfolio to create workflow solutions for cell therapythat will help investigators move their research applications intothe clinic more quickly and efficiently, while enhancing patientsafety,” said Paul Pickering, General Manager of Cell TherapySystems at Life Technologies. “We anticipate that this offeringwill enable us to form collaborations with key industry leaders,and help reduce their burden in qualifying tools and reagents asthey prepare to move their cell therapy concepts into the clinic,which will ultimately help improve the human condition and addressunmet medical need.”
1 Scientia Advisors new market review, quoted in April 23, 2010article from Fierce Biotech.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a globalbiotechnology tools company dedicated to improving the humancondition. Our systems, consumables and services enable researchersto accelerate scientific exploration, driving to discoveries anddevelopments that make life even better. Life Technologiescustomers do their work across the biological spectrum, working toadvance personalized medicine, regenerative science, moleculardiagnostics, agricultural and environmental research, and 21stcentury forensics. Life Technologies had sales of $3.3 billion in2009, employs approximately 9,000 people, has a presence inapproximately 160 countries, and possesses a rapidly growingintellectual property estate of approximately 3,900 patents andexclusive licenses. Life Technologies was created by thecombination of Invitrogen Corporation and Applied Biosystems Inc.,and manufactures both in-vitro diagnostic products and research useonly-labeled products. For more information on how we are making adifference, please visit our website:http://www.lifetechnologies.com.
Safe Harbor Statement
This press release includes forward-looking statements about ouranticipated results that involve risks and uncertainties. Some ofthe information contained in this press release, including, but notlimited to, statements as to industry trends and LifeTechnologies'''''''''''''''''''''''''''''''' plans, objectives,expectations and strategy for its business, containsforward-looking statements that are subject to risks anduncertainties that could cause actual results or events to differmaterially from those expressed or implied by such forward-lookingstatements. Any statements that are not statements of historicalfact are forward-looking statements. When used, the words"believe," "plan," "intend," "anticipate," "target," "estimate,""expect" and the like, and/or future tense or conditionalconstructions ("will," "may," "could," "should," etc.), or similarexpressions, identify certain of these forward-looking statements.Important factors which could cause actual results to differmaterially from those in the forward-looking statements aredetailed in filings made by Life Technologies with the Securitiesand Exchange Commission. Life Technologies undertakes no obligationto update or revise any such forward-looking statements to reflectsubsequent events or circumstances.
Products are For Research Use Only. Not intended for any animal orhuman therapeutic or diagnostic use.
Life Technologies Contact
